Stiris Research Inc. Announces the First Site Initiated in Paraoxysmal Nocturnal Hemoglobinuria Studies

London, ON — November 17, 2021 —

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces the first site initiated in a Paraoxysmal Nocturnal Hemoglobinuria (PNH) study.

The project team has worked through several challenges to get this first site activated on the two PNH studies we are working on. We are happy to have achieved this milestone for the client and look forward to the site identifying and screening patients in the coming weeks,” said Amanda Carrera, Vice President.

Paraoxysmal nocturnal hemoglobinuria (PNH) is a rare disorder of the blood in which red blood cells break apart prematurely. It is an acquired hematopoietic stem cell disorder that is characterized by destruction of red blood cells (hemolysis), blood clots, and impaired bone marrow function.

About Stiris Research

Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.

For more information, please contact:

Marketing – Stiris Research Inc.